Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723706 | 1.00 | MAOB (0.36) | MAOBKMT2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15723676 | 0.87 | MAOB (0.41) | MAOBKMT2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25758640 | 0.87 | MAOB (0.41) | MAOBKMT2ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL25758624 | 0.81 | BRD4 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL23836093 | 0.80 | MAOB (0.53) | MAOBKMT2AMEN1NPC1 | |
| SCHEMBL20371515 | 0.80 | MAOB (0.53) | MAOBKMT2AMEN1NPC1 | |
| SCHEMBL25758616 | 0.80 | CHRM1 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL25758574 | 0.80 | CHRM1 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL15723713 | 0.78 | SNCA (0.37) | KMT2AMEN1 | |
| SCHEMBL15723614 | 0.75 | HTR5A (0.36) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | MAOB 1859/4885KMT2A 3478/4885CHRNB2 4856/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | MAOB 1780/4885KMT2A 3383/4885CHRNB2 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.